Top HGH Brands for Optimal Growth & Performance

Human growth hormone (HGH) supplements have gained significant attention in the wellness and fitness communities, as they are often touted for their potential benefits in promoting muscle growth, improving recovery, and enhancing overall vitality. With numerous brands on the market, it can be overwhelming to choose the most reputable and effective options. This article aims to guide you through some of the top-rated HGH brands, evaluated based on their purity, user reviews, and overall effectiveness. Ready to explore your options and find the perfect fit for your needs? Read on to discover our curated list of the best HGH brands available today.

Illustration of hgh

Best brands of hgh in 2025

Norditropin

Norditropin, manufactured by Novo Nordisk, is a leading brand in the growth hormone deficiency market, known for its efficacy and safety in treating pediatric and adult patients. In 2023, it generated $1.6 billion in revenue, maintaining a significant market share, and is anticipated to grow at a CAGR of 4.9% from 2024 to 2032. Norditropin is indicated for various conditions, including growth hormone deficiency, Noonan syndrome, Turner syndrome, and idiopathic short stature. The product's user-friendly preloaded pen system and extensive clinical backing contribute to its market dominance. Hospital pharmacies led the market, commanding a 48% share in 2023. For more information on Norditropin's efficacy and safety, you can visit their website.

Genotropin

Genotropin, a recombinant human growth hormone, is a leading brand in the treatment of growth hormone deficiency, holding a 25% market share and generating $1.4 billion in revenue in 2023. It is indicated for various conditions, including pediatric growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, and idiopathic short stature. Genotropin is projected to grow to $2.1 billion by 2032, making it one of the fastest-growing segments in the market. Its efficacy and convenience, particularly through its subcutaneous administration, make it a preferred choice among patients. The product is widely used, with significant market presence and strong clinical backing. For more in-depth information, you can access the Genotropin growth hormone deficiency brochure.

Omnitrope

Omnitrope, a biosimilar recombinant human growth hormone (rhGH), is a leading treatment for growth hormone deficiency (GHD) and other growth-related conditions, approved in 2006. It is used to treat short stature in children due to GHD, Turner syndrome, and growth disturbances in chronic renal insufficiency, among other conditions. In a long-term study, 57.7% of patients had GHD, and the treatment showed significant efficacy with a mean treatment duration of 36.1 months. The global Omnitrope market is projected to reach USD 2,308.2 million by 2032, growing at a CAGR of 7.1%. Omnitrope is known for its effectiveness and safety, with treatment-related adverse events reported in 6.6% of patients.

Humatrope

Humatrope, a brand of somatropin produced through recombinant DNA technology, is a highly effective and widely used form of human growth hormone (hGH). It is synthesized in a modified strain of Escherichia coli and has an amino acid sequence identical to that of natural human growth hormone, comprising 191 amino acid residues and a molecular weight of about 22,125 daltons. For detailed information, you can refer to its FDA-approved labeling document.

Saizen

Saizen, produced by recombinant DNA technology, is a highly purified human growth hormone (hGH) with an amino acid sequence and structure identical to the dominant form of human pituitary growth hormone. It is manufactured by a modified mammalian cell line (mouse C127) and is available in 5 mg and 8.8 mg vials, making it a versatile treatment option for growth hormone deficiency. Saizen has been shown to promote organ weight increase, stimulate protein synthesis, and improve carbohydrate and lipid metabolism. In the growth hormone deficiency market, which is expected to grow at a CAGR of 5.0% from 2024 to 2032, Saizen is a significant player, particularly in North America, which holds a 40% market share. The product is administered subcutaneously, with dosages adjustable based on patient response and serum insulin-like growth factor (IGF-1) levels. For more comprehensive information, visit the Saizen product page.

Zomacton

Zomacton, produced by Ferring Pharmaceuticals, is a highly effective recombinant human growth hormone (somatropin) used to treat growth hormone deficiency in both children and adults. Approved by the FDA in 2015 for pediatric use and in 2018 for adult use, Zomacton has demonstrated significant efficacy in increasing lean body mass and reducing body fat, with studies showing a mean increase in lean body mass of 2.59kg and a reduction in body fat of 3.27kg in adult-onset GH deficiency patients. It is available in 5mg and 10mg strengths and can be administered via subcutaneous injection or the Zoma-Jet needle-free delivery device. Zomacton has been marketed globally since 1988 and is currently available in 47 countries. The treatment has also been shown to normalize low baseline HDL levels, with a mean change of 13.7mg/dL in adult-onset GH deficiency patients. For more information, visit the Zomacton product page.

Serostim

Serostim, produced by Merck Serono, is a leading brand of recombinant human growth hormone (hGH) used to treat HIV-associated wasting, increasing lean body mass, body weight, and physical endurance. It is administered subcutaneously at a recommended dose of 0.1 mg/kg daily, up to a total dose of 6 mg, and must be used in conjunction with antiretroviral therapy. Serostim has been shown to improve nitrogen balance, increase protein-sparing lipid oxidation, and retain essential minerals like phosphorous, potassium, and nitrogen. By Week 12 of treatment, the percentage of patients with serum IGF-1 SDS levels >= +2 increased to 80-90%. This therapy has been approved by the FDA and is a critical component in managing HIV-associated wasting. For more detailed information, visit their official Serostim page.

Hygetropin

Hygetropin, a prominent brand in the human growth hormone (HGH) market, is recognized for its high-quality products that cater to various medical needs, including growth hormone deficiency and other indications. The global HGH market, which includes brands like Hygetropin, is projected to grow at a CAGR of 8.1% from 2022 to 2032, reaching a market value of USD 7.3 billion by 2032. In 2022, the powder form of HGH, which Hygetropin may offer, accounted for 56.5% of product sales. The market is driven by increasing awareness of growth hormone deficits and the expanding healthcare infrastructure, particularly in North America, which holds the largest market share. Parenteral administration, a common route for HGH products like Hygetropin, was the most prevalent method in 2022.

Jintropin

Jintropin, a brand of recombinant human growth hormone (rhGH), is notable for its high quality and efficacy in treating growth hormone deficiencies. However, it is not as widely recognized or market-dominant as brands like Norditropin from Novo Nordisk, which led the global HGH market with a 28% market share by volume in 2013. Jintropin is manufactured by GeneScience Pharmaceuticals and enjoys popularity in certain regions, particularly in Asia. Despite its reputation, it lacks the extensive clinical backing and global market presence of leading brands. The product is often associated with athletic and bodybuilding communities, though its use is strictly regulated and primarily intended for medical purposes. For more detailed information, visit Jintropin's official page on the GeneScience Pharmaceuticals website.

Ansomone

Ansomone, a brand of recombinant human growth hormone (HGH), is renowned for its high quality and efficacy, produced through advanced genetic engineering techniques. It is used to treat growth hormone deficiency in children and adults, promoting significant improvements in growth and metabolic functions. Studies have shown that HGH therapy can increase total body lean mass by up to 1.6 kg and reduce trunk fat by as much as 1.67% over a period of several weeks. The pulsatile release mechanism of HGH, mimicked by Ansomone, ensures a natural and effective treatment regimen. With strict quality control and adherence to international standards, Ansomone has become a trusted name in the field of HGH therapy. For more information, visit the Ansomone product page.